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Abstract
Reporting bias represents a major problem in the assessment of health care interventions. Several prominent cases 
have been described in the literature, for example, in the reporting of trials of antidepressants, Class I anti-arrhythmic 
drugs, and selective COX-2 inhibitors. The aim of this narrative review is to gain an overview of reporting bias in the 
medical literature, focussing on publication bias and selective outcome reporting. We explore whether these types of 
bias have been shown in areas beyond the well-known cases noted above, in order to gain an impression of how 
widespread the problem is. For this purpose, we screened relevant articles on reporting bias that had previously been 
obtained by the German Institute for Quality and Efficiency in Health Care in the context of its health technology 
assessment reports and other research work, together with the reference lists of these articles.
We identified reporting bias in 40 indications comprising around 50 different pharmacological, surgical (e.g. vacuum-
assisted closure therapy), diagnostic (e.g. ultrasound), and preventive (e.g. cancer vaccines) interventions. Regarding 
pharmacological interventions, cases of reporting bias were, for example, identified in the treatment of the following 
conditions: depression, bipolar disorder, schizophrenia, anxiety disorder, attention-deficit hyperactivity disorder, 
Alzheimer's disease, pain, migraine, cardiovascular disease, gastric ulcers, irritable bowel syndrome, urinary 
incontinence, atopic dermatitis, diabetes mellitus type 2, hypercholesterolaemia, thyroid disorders, menopausal 
symptoms, various types of cancer (e.g. ovarian cancer and melanoma), various types of infections (e.g. HIV, influenza 
and Hepatitis B), and acute trauma. Many cases involved the withholding of study data by manufacturers and 
regulatory agencies or the active attempt by manufacturers to suppress publication. The ascertained effects of 
reporting bias included the overestimation of efficacy and the underestimation of safety risks of interventions.
In conclusion, reporting bias is a widespread phenomenon in the medical literature. Mandatory prospective 
registration of trials and public access to study data via results databases need to be introduced on a worldwide scale. 
This will allow for an independent review of research data, help fulfil ethical obligations towards patients, and ensure a 
basis for fully-informed decision making in the health care system.
Background
The reporting of research findings may depend on the
nature and direction of results, which is referred to as
"reporting bias" [1,2]. For example, studies in which inter-
ventions are shown to be ineffective are sometimes not
published, meaning that only a subset of the relevant evi-
dence on a topic may be available [1,2]. Various types of
reporting bias exist (Table 1), including publication bias
and outcome reporting bias, which concern bias from
missing outcome data on 2 levels: the study level, i.e.
"non-publication due to lack of submission or rejection of
study reports", and the outcome level, i.e. "the selective
non-reporting of outcomes within published studies" [3].
Reporting bias on a study level
Results of clinical research are largely underreported or
reported with delay. Various analyses of research proto-
cols submitted to institutional review boards and
research ethics committees in Europe, the United States,
and Australia found that on average, only about half of
the protocols had been published, with higher publica-
tion rates in Anglo-Saxon countries [4-10].
Similar analyses have been performed of trials submit-
ted to regulatory authorities: a cohort study of trials sup-
porting new drugs approved by the Food and Drug
Administration (FDA) identified over 900 trials of 90 new
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drugs in FDA reviews; only 43% of the trials were pub-
lished [11]. Wide variations in publication rates have
been shown for specific indications [12-16]. The selective
submission of clinical trials with positive outcomes to
regulatory authorities has also been described [17]. Even
if trials are published, the time lapse until publication
may be substantial [8,18,19].
There is no simple classification of a clinical trial into
"published" or "unpublished", as varying degrees of publi-
cation exist. These range from full-text publications in
peer-reviewed journals that are easily identifiable
through a search in bibliographic databases, to study
information entered in trial registries, so-called grey liter-
ature (e.g. abstracts and working papers), and data on file
in drug companies and regulatory agencies, which may or
may not be provided to health technology assessment
(HTA) agencies or other researchers after being
requested. If such data are transmitted, they may then be
fully published or not (e.g. the German Institute for Qual-
ity and Efficiency in Health Care [Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen, IQWiG]
publishes all data used in its assessment reports [20],
whereas the UK National Institute for Clinical Excellence
[NICE] may accept "commercial in confidence" data [21]).
Even if studies are presented at meetings, this does not
necessarily mean subsequent full publication: an analysis
of nearly 30,000 meeting abstracts from various disci-
plines found a publication rate of 63% for randomized or
controlled clinical trials [22].
Reporting bias on an outcome level
Selective reporting within a study may involve (a) selec-
tive reporting of analyses or (b) selective reporting of out-
comes. This may include, for example, the reporting of (a)
per-protocol (PP) versus intention-to-treat (ITT) analy-
ses or adjusted versus unadjusted analyses, and (b) out-
comes from different time points or statistically
significant versus non-significant outcomes [3,23].
Various reviews have found extensive selective report-
ing in study publications [3,14,24-28]. For example, com-
parisons of publications with study protocols have shown
that primary outcomes had been newly introduced, omit-
ted, or changed in about 40% to 60% of cases [3,24].
Selective reporting particularly concerns the underre-
porting of adverse events [12,29-32]. For example, an
analysis of 192 randomized drug trials in various indica-
tions showed that only 46% of publications stated the fre-
quency of specific reasons for treatment discontinuation
due to toxicity [29]. Outcomes are not only selectively
reported, but negative results are reported in a positive
manner and conclusions are often not supported by
results data [16,26,33-35]. For instance, a comparison of
study characteristics reported in FDA reviews of New
Drug Applications (NDAs) with those reported in publi-
cations found that 9 of 99 conclusions had been changed
in the publications, all in favour of the new drug [26].
Factors associated with reporting bias
Characteristics of published studies
The fact that studies with positive or favourable results
are more likely to be published than those with negative
or unfavourable results was already addressed in the
1950s [36], and has since been widely confirmed [3,6-
8,14,37-40]. Studies with positive or favourable results
have been associated with various other factors such as
faster publication [8,18,19,37], publication in higher
impact factor journals [7,41], a greater number of publi-
cations [7] (including covert duplicate publications [42]),
Table 1: Definitions of some types of reporting bias1
Type of reporting bias Definition
Publication bias The publication or non-
publication of research 
findings, depending on the 
nature and direction of the 
results
Time lag bias The rapid or delayed 
publication of research 
findings, depending on the 
nature and direction of the 
results
Multiple (duplicate) 
publication bias
The multiple or singular 
publication of research 
findings, depending on the 
nature and direction of the 
results
Location bias The publication of research 
findings in journals with 
different ease of access or 
levels of indexing in standard 
databases, depending on the 
nature and direction of 
results
Citation bias The citation or non-citation of 
research findings, depending 
on the nature and direction 
of the results
Language bias The publication of research 
findings in a particular 
language, depending on the 
nature and direction of the 
results
Outcome reporting bias The selective reporting of 
some outcomes but not 
others, depending on the 
nature and direction of the 
results
1Table 10.1.a, Chapter 10 of the Cochrane Handbook for 
Systematic Reviews of Interventions [2]. © The Cochrane 
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more frequent citation [43-45], and more likely publica-
tion in English [46].
Several other factors have been linked to successful
publication, for example, methodological quality [47],
study type [47], sample size [5,7,48], multicentre status
[5,6,41], and non-commercial funding [5,6,49,50]. How-
ever, for some factors, these associations are inconsistent
[6,37].
Submission and rejection of studies
One of the main reasons for the non-publication of nega-
tive studies seems to be the non-submission of manu-
scripts by investigators, not the rejection of manuscripts
by medical journals. A follow-up of studies approved by
US institutional review boards showed that only 6 of 124
unpublished studies had actually been rejected for publi-
cation [6]. A prospective cohort study of 745 manuscripts
submitted to JAMA showed no statistically significant
difference in publication rates between studies with posi-
tive and those with negative results [51], which has been
confirmed by further analyses of other journals [47,52].
Author surveys have shown that the most common rea-
sons for not submitting papers were negative results and
a lack of interest, time, or other resources [39-41,53].
The role of the pharmaceutical industry
An association has been shown between industry spon-
sorship or industry affiliation of authors and positive
research outcomes and conclusions, both in publications
of primary studies and in systematic reviews [49,54-63].
For example, in a systematic review of the scope and
impact of financial conflicts of interest in biomedical
research, an aggregation of the results of 8 analyses of the
relation between industry sponsorship and outcomes
showed a statistically significant association between
industry sponsorship and pro-industry conclusions [55].
A comparison of the methodological quality and conclu-
sions in Cochrane reviews with those in industry-sup-
ported meta-analyses found that the latter were less
transparent, less critical of methodological limitations of
the included trials, and drew more favourable conclu-
sions [57]. In addition, publication constraints and active
attempts to prevent publication have been identified in
industry-sponsored research [55,64-68]. Other aspects of
industry involvement, such as design bias, are beyond the
scope of this paper.
Rationale, aim and procedure
IQWiG produces HTA reports of drug and non-drug
interventions for the decision-making body of the statu-
tory health care funds, the Federal Joint Committee. The
process of report production includes requesting infor-
mation on published and unpublished studies from man-
ufacturers; unfortunately, compliance by manufacturers
is inconsistent, as recently shown in the attempted con-
cealment of studies on antidepressants [69]. Reporting
bias in antidepressant research has been shown before
[16,70]; other well-known cases include Class I anti-
arrhythmic drugs [71,72] and selective COX-2 inhibitors
[73,74].
The aim of this narrative review was to gain an over-
view of reporting bias in the medical literature, focussing
on publication bias and selective outcome reporting. We
wished to explore whether this type of bias has been
shown in areas beyond the well-known cases noted
a bo v e ,  i n  o r d e r  t o  o b t a i n  a n  i m p r e s s i o n  o f  h o w  w i d e -
spread this problem is. The review was based on the
screening of full-text publications on reporting bias that
had either been obtained by the Institute in the context of
its HTA reports and other research work or were identi-
fied by the screening of the reference lists of the on-site
publications. The retrieved examples were organized
according to indications and interventions. We also dis-
cuss the effects of reporting bias, as well as the measures
that have been implemented to solve this problem.
The term "reporting bias" traditionally refers to the
reporting of clinical trials and other types of studies; if
one extends this term beyond experimental settings, for
example, to the withholding of information on any bene-
ficial medical innovation, then an early example of
reporting bias was noted by Rosenberg in his article
"Secrecy in medical research", which describes the inven-
tion of the obstetrical forceps. This device was developed
by the Chamberlen brothers in Europe in the 17th cen-
tury; however, it was kept secret for commercial reasons
for 3 generations and as a result, many women and neo-
nates died during childbirth [75]. In the context of our
p a p e r ,  w e  a l s o  c o n s i d e r e d  t h i s  e x t e n d e d  d e f i n i t i o n  o f
reporting bias.
Findings
We identified reporting bias in 40 indications comprising
around 50 different interventions. Examples were found
in various sources, e.g. journal articles of published ver-
sus unpublished data, reviews of reporting bias, editori-
als, letters to the editor, newspaper reports, expert and
government reports, books, and online sources. The fol-
lowing text summarizes the information presented in
these examples. More details and references to the back-
ground literature are included in Additional file 1: Table
S2.
Mental and behavioural disorders
Reporting bias is common in psychiatric research (see
below). This also includes industry-sponsorship bias [76-
82].
Depression
Turner et al compared FDA reviews of antidepressant tri-
als including over 12,000 patients with the matching pub-
lications and found that 37 out of 38 trials viewed asMcGauran et al. Trials 2010, 11:37
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positive by the FDA were published [16]. Of the 36 trials
having negative or questionable results according to the
FDA, 22 were unpublished and 11 of the 14 published
studies conveyed a positive outcome. According to the
publications, 94% of the trials had positive results, which
was in contrast to the proportion reported by the FDA
(51%). The overall increase in effect size in the published
trials was 32%. In a meta-analysis of data from antide-
pressant trials submitted to the FDA, Kirsch et al
requested data on 6 antidepressants from the FDA under
the Freedom of Information Act. However, the FDA did
not disclose relevant data from 9 of 47 trials, all of which
failed to show a statistically significant benefit over pla-
cebo. Data from 4 of these trials were available on the
GlaxoSmithKline (GSK) website. In total, the missing
data represented 38% of patients in sertraline trials and
23% of patients in citalopram trials. The analysis of trials
investigating the 4 remaining antidepressants showed
that drug-placebo differences in antidepressant efficacy
were relatively small, even for severely depressed patients
[83].
Selective serotonin reuptake inhibitors (SSRIs) One of
the biggest controversies surrounding unpublished data
was the withholding of efficacy and safety data from SSRI
trials. In a lawsuit launched by the Attorney General of
the State of New York it was alleged that GSK had pub-
lished positive information about the paediatric use of
paroxetine in major depressive disorder (MDD), but had
concealed negative safety and efficacy data [84]. The
company had conducted at least 5 trials on the off-label
use of paroxetine in children and adolescents but pub-
lished only one, which showed mixed results for efficacy.
The results of the other trials, which did not demonstrate
efficacy and suggested a possible increased risk of sui-
cidality, were suppressed [84]. As part of a legal settle-
ment, GSK agreed to establish an online clinical trials
registry containing results summaries for all GSK-spon-
sored studies conducted after a set date [85,86].
Whittington et al performed a systematic review of
published versus unpublished data on SSRIs in childhood
depression. While published data indicated a favourable
risk-benefit profile for some SSRIs, the inclusion of
unpublished data indicated a potentially unfavourable
risk-benefit profile for all SSRIs investigated except fluox-
etine [70].
Newer antidepressants IQWiG published the prelimi-
nary results of an HTA report on reboxetine, a selective
norepinephrine reuptake inhibitor, and other antidepres-
sants. At least 4600 patients had participated in 16 rebox-
etine trials, but the majority of data were unpublished.
Despite a request for information the manufacturer
Pfizer refused to provide these data. Only data on about
1600 patients were analysable and IQWiG concluded that
due to the risk of publication bias, no statement on the
benefit or harm of reboxetine could be made [69,87]. The
preliminary HTA report mentioned above also included
an assessment of mirtazapine, a noradrenergic and spe-
cific serotonergic antidepressant. Four potentially rele-
vant trials were identified in addition to 27 trials included
in the assessment, but the manufacturer Essex Pharma
did not provide the study reports. Regarding the other
trials, the manufacturer did not send the complete study
reports, so the full analyses were not available. IQW iG
concluded that the results of the assessment of mirtazap-
ine may have been biased by unpublished data [69,87].
After the behaviour of Pfizer and Essex Pharma had been
widely publicized, the companies provided the majority
of study reports for the final HTA report. The prelimi-
nary report's conclusion on the effects of mirtazapine was
not affected by the additional data. For reboxetine, the
analysis of the published and unpublished data changed
the conclusion from "no statement possible" to "no bene-
fit proven" [88].
Bipolar disorder
Lamotrigine A review by Nassir Ghaemi et al of data on
lamotrigine in bipolar disorder provided on the GSK
website showed that data from negative trials were avail-
able on the website but that the studies had not been pub-
lished in detail or publications emphasized positive
secondary outcomes instead of negative primary ones.
Outside of the primary area of efficacy (prophylaxis of
mood episodes), the drug showed very limited efficacy in
indications such as acute bipolar depression, for which
clinicians were supporting its use [35].
Gabapentin Gabapentin, a GABA analogue, was
approved by the FDA in 1993 for a certain type of epi-
lepsy, and in 2002 for postherpetic neuralgia. As of Feb-
ruary 1996, 83% of gabapentin use was for epilepsy, and
17% for off-label indications (see the expert report by
Abramson [89]). As the result of a comprehensive mar-
keting campaign by Pfizer, the number of patients in the
US taking gabapentin rose from about 430,000 to nearly 6
million between 1996 and 2001; this increase was solely
due to off-label use for indications, including bipolar dis-
order. As of September 2001, 93.5% of gabapentin use
was for off-label indications [89]. In a further expert
report, Dickersin noted "extensive evidence of reporting
bias" [34], which she further analysed in a recent publica-
tion with Vedula et al [90]. Concerning the trials of gaba-
pentin for bipolar disorders, 2 of the 3 trials (all
published) were negative for the primary outcome. How-
ever, these publications showed "extensive spin and mis-
representation of data" [34].
Schizophrenia
Quetiapine The Washington Post reported that a trial on
quetiapine, an atypical antipsychotic, was "silenced" in
1997, the same year it was approved by the FDA to treat
schizophrenia. The study ("Study 15") was not published.McGauran et al. Trials 2010, 11:37
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Patients taking quetiapine had shown high rates of treat-
ment discontinuations and had experienced significant
weight increases. However, data presented by the manu-
facturer AstraZeneca in 1999 at European and US meet-
ings actually indicated that the drug helped psychotic
patients lose weight [91].
Panic disorder
Paroxetine Turner described an example of reporting
bias in the treatment of panic disorder: according to a
review article, 3 "well designed studies" had apparently
shown that the controlled-release formulation of parox-
etine had been effective in patients with this condition.
However, according to the corresponding FDA statistical
review, only one study was strongly positive, the second
study was non-significant regarding the primary outcome
(and marginally significant for a secondary outcome), and
the third study was clearly negative [92].
Further examples of reporting bias in research on men-
tal and behavioural disorders are included in Additional
file 1: Table S2.
Disorders of the nervous system
Alzheimer's disease
Rofecoxib Internal company analyses and information
provided by the manufacturer Merck & Co to the FDA on
rofecoxib, a selective COX-2 inhibitor, were released dur-
ing litigation procedures. The documents referred to tri-
als investigating the effects of rofecoxib on the
occurrence or progression of Alzheimer's disease. Psaty
and Kronmal performed a review of these documents and
2 trial publications and showed that, although presenting
mortality data, the publications had not included analyses
or statistical tests of these data and both had concluded
that regarding safety, rofecoxib was "well tolerated". In
contrast, in April 2001, Merck's internal ITT analyses of
pooled data from these 2 trials showed a significant
increase in total mortality. However, this information was
neither disclosed to the FDA nor published in a timely
fashion [74]. Rofecoxib was taken off the market by
Merck in 2004 [93], among allegations that the company
had been aware of the safety risks since 2000 [73].
Acute pain
Valdecoxib In their article "An untold story?", Lenzer and
Brownlee reported the case of valdecoxib, another selec-
tive COX-2 inhibitor withdrawn from the market due to
cardiovascular concerns [94,95]. In 2001, the manufac-
turer Pfizer had applied for approval in 4 indications,
including acute pain. The application for acute pain was
rejected and some of the information about the corre-
sponding trials removed from the FDA website for confi-
dentiality reasons. Further examples of reporting bias in
research on pain are presented in Additional file 1: Table
S2.
Migraine
Gabapentin According to the expert report by Dickersin,
all 3 trials on gabapentin for migraine showed negative
results for the primary outcome. Substantial reporting
bias was present. One trial was fully published (seemingly
with a redefined primary outcome showing positive
results in a subgroup of patients), one was unpublished,
and preliminary (positive) results were presented for the
third trial [34].
Disorders of the circulatory system
Coronary heart disease (bleeding prophylaxis during bypass 
surgery)
Aprotinin In his article on observational studies on drug
safety, Hiatt reported the case of aprotinin, an antifibrin-
olytic drug formerly marketed to reduce bleeding during
heart bypass graft surgery. In 2006, data from 2 published
observational studies indicated serious concerns about
the drug's safety [96]. The FDA subsequently convened
an expert meeting in which the safety data presented by
the manufacturer Bayer did not reveal any increased risk
of fatal or nonfatal cardiovascular events. However, it
turned out that Bayer had not presented additional obser-
vational data, which, according to an FDA review, indi-
cated that aprotinin may be associated with an increased
risk of death and other serious adverse events. In Novem-
ber 2007 Bayer suspended the worldwide marketing of
aprotinin, after requests and advice from various drug
regulating authorities [97].
Prevention of arrhythmia
Class I anti-arrhythmic drugs In a clinical trial con-
ducted in 1980, 9 out of 49 patients with suspected acute
myocardial infarction treated with a class Ic anti-arrhyth-
mic drug (lorcainide) died, versus only one patient in the
placebo group; the investigators interpreted this finding
as an "effect of chance" [71]. The development of lorcain-
ide was discontinued for commercial reasons, and the
results of the trial were not published until 1993. The
investigators then stated that if the trial had been pub-
lished earlier, it "might have provided an early warning of
trouble ahead" [71]. Instead, during the 1980s, class I
drugs were widely used, even though concerns as to their
lack of effect were published as early as 1983 [98,99]. Fur-
ther reviews and trials confirmed this suspicion, as well as
an increase in mortality [100-102]. In his book "Deadly
Medicine", Moore described the consequences as "Amer-
ica's worst drug disaster", which had "produced a death
toll larger than the United States' combat losses in wars
such as Korea and Vietnam" [72]. Further examples of
reporting bias in research on disorders of the circulatory
system are presented in Additional file 1: Table S2.McGauran et al. Trials 2010, 11:37
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Disorders of the digestive system
Irritable bowel syndrome
Alosetron Barbehenn et al compared a published trial on
alosetron, a 5-HT3 antagonist, in women with irritable
bowel syndrome with data obtained from the FDA [103].
She noted that according to the graphics in the publica-
tion, which presented relative differences in pain and dis-
comfort scores, the drug seemed effective. However,
when plotting the absolute data from the FDA review, the
d a t a  po i n t s  w e r e  a l m o s t  s u pe r i m po s a b l e .  A f t e r  d i s c u s-
sions with the FDA about potential serious side effects,
the drug was withdrawn from the market by the manu-
facturer in 2000, but reapproved with restrictions in 2002
[104]. A further example of reporting bias in research on
disorders of the digestive system is presented in Addi-
tional file 1: Table S2.
Disorders of the genitourinary system/Perinatal medicine
Urinary incontinence
Duloxetine Lenzer and Brownlee also reported cases of
suicide in a trial investigating the selective serotonin and
noradrenalin reuptake inhibitor duloxetine for a new
indication, urinary incontinence in women. However, the
FDA refused to release data on these cases, citing trade
secrecy laws. These laws "permit companies to withhold
all information, even deaths, about drugs that do not win
approval for a new indication, even when the drug is
already on the market for other indications" [94]. Two
examples of reporting bias in perinatal research are pre-
sented in Additional file 1: Table S2.
Disorders of the musculoskeletal system
Osteoarthritis
Rofecoxib In 2000, a trial comparing upper gastrointesti-
nal toxicity of rofecoxib, a selective COX-2 inhibitor, and
naproxen in over 8000 patients with rheumatoid arthritis
reported that rofecoxib was associated with significantly
fewer clinically important upper gastrointestinal events.
The significantly lower myocardial infarction rate in the
naproxen group was attributed to a cardioprotective
effect of naproxen (VIGOR trial, [105]). Concerns about
the risk of selective COX-2-inhibitor-related cardiovascu-
lar events were raised as early as 2001 [106], and in 2002,
an analysis including previously unpublished data from
FDA reports of the VIGOR trial showed a statistically sig-
nificant increase of serious cardiovascular thrombotic
events in patients using rofecoxib [107].
Celecoxib In their article on access to pharmaceutical
data at the FDA, Lurie and Zieve presented the example
of the selective COX-2 inhibitor celecoxib: in a journal
publication of a trial investigating the gastrointestinal
toxicity with celecoxib versus other pain medications, the
study authors concluded that the drug was associated
with a lower incidence of gastrointestinal ulcers after 6
months of therapy [108,109]. However, they failed to dis-
close that at the time of publication they had already
received data for the full study period (12 months), which
showed no advantage over the comparator drugs for the
above outcome [109].
Disorders of the skin
Atopic dermatitis
Evening primrose oil In his editorial "Evening primrose
oil for atopic dermatitis - Time to say goodnight", Wil-
liams reported that he and his colleague, who had per-
formed an individual patient meta-analysis of evening
primrose oil for atopic dermatitis commissioned by the
UK Department of Health, were not given permission to
publish their report, which included 10 previously
unpublished studies. After submission of the report to
the Department of Health, Searle, the company then
responsible for product marketing, required the authors
and referees to sign a written statement that the contents
of the report had not been leaked. Other research had not
shown convincing evidence of a benefit, and in 2002 the
UK Medicines Control Agency withdrew marketing
authorisation [66].
Endocrine and metabolic disorders
Diabetes mellitus type 2
Rosiglitazone The US cardiologist Steven Nissen com-
mented on safety issues surrounding rosiglitazone, a thi-
azolidinedione used to treat type 2 diabetes. After the
drug's approval, the FDA was informed in August 2005 by
the manufacturer GSK that it had performed a meta-
analysis of 42 randomized clinical trials of rosiglitazone,
which suggested a 31% increase in the risk of ischaemic
cardiovascular complications. GSK posted this finding on
its website. However, neither GSK nor the FDA dissemi-
nated their findings in a broad way to the scientific com-
munity and the public [110]. The safety concerns were
supported by a controversially discussed meta-analysis
performed by Nissen and Wolski, who found that treat-
ment with rosiglitazone was associated with a signifi-
cantly increased risk of myocardial infarction and an
increase in the risk of death from cardiovascular causes
that had borderline significance [111]. More examples of
reporting bias in diabetes research are presented in Addi-
tional file 1: Table S2.
Hypercholesterolaemia
Ezetimibe and simvastatin In his article "Controversies
surround heart drug study" Mitka described a trial that
compared the 2 anticholesterol drugs ezetimibe and sim-
vastatin versus simvastatin alone in patients with
heterozygous familial hypercholesterolaemia [112]. No
statistically significant difference between treatment
groups was found for the primary outcome (mean change
in the carotid intima-media thickness) after 2 years [113].McGauran et al. Trials 2010, 11:37
http://www.trialsjournal.com/content/11/1/37
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The trial, which was sponsored by Merck & Co. and
Schering-Plough, was concluded in April 2006. A delay of
almost 2 years in the reporting of results followed amidst
allegations that the manufacturers had attempted to
change the study endpoints prior to the publication of
results [112]. A further case of reporting bias in research
on ezetimibe is included in Additional file 1: Table S2.
Cerivastatin Psaty et al conducted a review of the pub-
lished literature on the statin cerivastatin and also analy-
sed internal company documents that became available
during litigation procedures [114]. In the published liter-
ature, cerivastatin was associated with a substantially
higher risk of rhabdomyolysis than other statins; this par-
ticularly referred to cerivastatin-gemfibrozil combination
therapy. Cerivastatin was launched in the US in 1998 by
Bayer, and within 3 to 4 months, internal documents indi-
cated there had been multiple cases of cerivastatin-gemfi-
brozil interactions. However, it took more than 18
months until a contraindication about the concomitant
use of the 2 drugs was added to the package insert. The
unpublished data available in 1999 also suggested an
association between high-dose cerivastatin monotherapy
and rhabdomyolysis. In 1999/2000, the company analysed
FDA adverse event reporting system data, which sug-
gested that compared with atorvastatin, cerivastatin
monotherapy substantially increased the risk of rhab-
domyolysis. However, these findings were not dissemi-
nated or published. Cerivastatin was removed from the
market in August 2001 [114]. In the same month, the
German Ministry of Health accused Bayer of withholding
vital information from its federal drug agency [115].
Thyroid disorders
Levothyroxine The Wall Street Journal reported the sup-
pression of the results of a trial comparing the bioavail-
ability of generic and brand-name levothyroxine products
in the treatment of hypothyroidism; the investigators had
concluded that the products were bioequivalent and in
most cases interchangeable [116,117]. The trial was com-
pleted in 1990; over the next 7 years, the manufacturer of
the brand-name product Synthroid, Boots pharmaceuti-
cals, successfully delayed publication [65]. The manu-
script was finally published in 1997.
Menopausal symptoms
Tibolone A study investigating tibolone, a synthetic ste-
roid, in breast-cancer patients with climacteric com-
plaints was terminated prematurely after it was shown
that this drug significantly increased the risk of cancer
recurrence [118]. According to the German TV pro-
gramme Frontal 21, the manufacturer (Schering-Plough,
formerly NV Organon) informed regulatory authorities
and ethics committees, as well as study centres and par-
ticipants. However, the study results were not published
until 1.5 years later [119].
Neoplasms
Oncology is another area in which reporting bias is com-
mon [40,50,54,120-127]. A review of over 2000 oncology
trials registered in ClinicalTrials.gov showed that less
than 20% were available in PubMed, with substantial dif-
ferences between trials sponsored by clinical trial net-
works and those sponsored by industry regarding both
publication rates (59% vs. 6%) and the proportion of trials
with positive results (50% vs. 75%) [50].
Ovarian cancer
Combination chemotherapy In one of the earliest publi-
cations measuring the effects of reporting bias, Simes
compared published oncology trials and trials identified
in cancer registries that investigated the survival impact
of initial alkylating agent (AA) therapy versus combina-
tion chemotherapy (CC) in advanced ovarian cancer. A
meta-analysis of the published trials showed a significant
survival advantage for CC; however, no such advantage
was shown in the meta-analysis of registered trials [121].
Multiple myeloma
Combination chemotherapy The above study also
investigated the survival impact of AA/prednisone versus
CC in multiple myeloma. The meta-analysis of published
trials demonstrated a significant survival advantage for
CC. A survival benefit was also shown in the registered
trials; however, the estimated magnitude of the benefit
was reduced [121]. A further example of reporting bias in
cancer research is presented in Additional file 1: Table S2.
Disorders of the blood
Thalassaemia major
Iron-chelation agents In his editorial "Thyroid storm",
Rennie, among other things, discussed events surround-
ing a US researcher who had been involved in a trial
investigating the effects of an oral iron-chelation agent in
patients with thalassaemia major. She had initially pub-
lished an optimistic article on the effects of this agent.
However, further research showed a lack of effectiveness
and a potential safety risk. She had signed a confidential-
ity agreement but, because of her concerns, decided to
break confidentiality and report her results at a meeting;
the manufacturer unsuccessfully attempted to block her
presentation [128].
Bacterial, fungal, and viral infections
Influenza
Oseltamivir The BMJ and Channel 4 News reported on
the difficulties in obtaining data for an updated Cochrane
review on neuraminidase inhibitors in influenza [129]. A
previous analysis of oseltamivir, which was used in the
prior Cochrane review [130], was based on 10 industry-
sponsored trials of which only 2 had been published in
peer-reviewed journals [131]. The manufacturer Roche
initially declined to provide the necessary data to repro-McGauran et al. Trials 2010, 11:37
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duce the analysis and then only provided a selection of
files [129]. The Cochrane authors (Jefferson et al) subse-
quently concluded that "Evidence on the effects of oselta-
mivir in complications from lower respiratory tract
infections, reported in our 2006 Cochrane review, may be
unreliable" [132]. Roche has since agreed to provide pub-
lic access to study summaries and password-protected
access to the full study reports [129].
HIV/AIDS
Anti-HIV agents Ioannidis et al identified several exam-
ples of publication bias in trials investigating medications
against HIV. At least 13 trials of 6 antiviral agents includ-
ing at least 3779 patients had remained unpublished for
more than 3 years from the time of their meeting presen-
tation or completion. At least 9 of these trials had nega-
tive preliminary or final results. For example, 2 large
negative isoprinosine trials were unpublished, whilst a
positive trial had been published in a high impact journal
[33]. Further examples of reporting bias in research on
infections are presented in Additional file 1: Table S2.
Acute trauma
Acute spinal cord injury
High-dose steroids Lenzer and Brownlee described the
concerns of neurosurgeons regarding the use of high-
dose steroids in patients with acute spinal cord injury.
They noted that one neurosurgeon believed that several
thousand patients had died as a result of this interven-
tion; 2 surveys showed that many other neurosurgeons
shared his concerns. The single available study, which had
been funded by the NIH, was potentially flawed and sev-
eral researchers had unsuccessfully lobbied for the release
of the underlying data [94].
Shock
Human albumin infusion In the UK Health Commit-
tee's 2004-2005 report on the influence of the pharma-
ceutical industry, Chalmers mentioned a systematic
review of human albumin solution, which is used in the
treatment of shock, e.g. in patients with burns. The
results showed no evidence that albumin was helpful and
suggested that this intervention may actually be harmful.
Although the UK Medicines Control Agency subse-
quently slightly modified the labelling, it kept confidential
the evidence upon which the drug had been re-licensed in
1993 [133,134].
Vaccinations
HIV-1 vaccine
McCarthy reported the case of an HIV-1 vaccine study
that was terminated early when no difference in efficacy
between the vaccine and placebo was found. After the
lead investigators refused to include a post-hoc analysis
arguing that it had not been part of the study protocol
and that invalid statistical methods had been used, the
manufacturer, Immune Response, filed an (unsuccessful)
claim seeking to prevent publication. After publication,
the manufacturer filed a claim against the study's lead
investigators and their universities asking for US $7-10
million in damages [135].
Cancer vaccines
Rosenberg provided various examples of how researchers
and companies withheld information on cancer vaccines
for competitive reasons; for example, researchers were
asked to keep information confidential that might have
prevented cancer patients from receiving ineffective or
even harmful doses of a new agent [75].
Other indications
Nocturnal leg cramps
Quinine Man-Song-Hing et al performed a meta-analy-
sis including unpublished individual patient data (IPD)
obtained from the FDA on trials investigating quinine for
the treatment of nocturnal leg cramps. They showed that
the pooling only of published studies overestimated effi-
cacy by more than 100% [136]. Further examples of
reporting bias in other indications are presented in Addi-
tional file 1: Table S2.
Further research areas
Reporting bias has also been shown in other research
areas, such as genetics [137,138], effects of passive smok-
ing [139,140] and nicotine [141,142], and effects of air
pollution [143].
Discussion
The numerous examples identified show that reporting
bias concerns not only previously highlighted therapies
such as antidepressants, pain medication, or cancer
drugs, but affects a wide range of indications and inter-
ventions. Many cases involved the withholding of study
data by manufacturers and regulatory agencies or the
active attempt to suppress publication by manufacturers,
which either resulted in substantial delays in publication
(time-lag bias) or no publication at all.
Limitations of the review
The review does not provide a complete overview of
reporting bias in clinical research. Although our efforts to
identify relevant literature went beyond the usual efforts
applied in narrative reviews, the review is non-systematic
and we emphasized this feature in the title. A substantial
amount of relevant literature was available in-house and
further relevant literature was obtained by screening ref-
erence lists. We dispensed with our initial plan to con-
duct a systematic review to identify cases of reporting
bias, as we noticed that many cases were not identifiable
by screening titles and abstracts of citations from biblio-
graphic databases, but were "hidden" in the discussion
sections of journal articles or mentioned in other sourcesMcGauran et al. Trials 2010, 11:37
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such as newspapers, books, government reports or web-
sites. As a search of bibliographic databases and the
Internet using keywords related to reporting bias pro-
duces thousands of potentially relevant hits, we would
therefore have had to obtain and read an excessive
amount of full texts in order to ensure that we had not
missed any examples. This was not feasible due to
resource limitations. However, within the framework of a
previous publication [144] we had conducted a literature
search in PubMed, and some of the citations retrieved
formed the basis of our literature pool for the current
review. In spite of this non-systematic approach, we were
a b l e  t o  i d e n t i f y  d o z e n s  o f  c a s e s  o f  r e p o r t i n g  b i a s  i n
numerous indications.
Another potential limitation of the review is the validity
of the sources describing cases of reporting bias.
A l t h o u g h  t h e  m a j o r i t y  o f  e x a m p l e s  w e r e  i d e n t i f i e d  i n
peer-reviewed journals, several cases were based on
information from other sources such as newspaper arti-
cles and websites. However, we also regard these sources
to be valuable as they provide a broader overview of
reporting bias beyond well-known examples and also
offer a starting point for more systematic research on the
additional examples identified.
Effects of reporting bias
Published evidence tends to overestimate efficacy and
underestimate safety risks. The extent of misestimation is
often unknown. The few identified comparisons that
quantified overestimates of treatment effects in fully pub-
lished versus unpublished or not fully published data
showed wide variations in their results. Comparisons of
pooled published versus pooled published and unpub-
lished FDA data showed a greater treatment effect of 11%
to 69% for individual antidepressants, 32% for the class of
antidepressants [16], and over 100% for an agent to treat
nocturnal leg cramps [136]. In addition, published studies
have shown a 9% to 15% greater treatment effect than
grey literature studies [145,146]. Thus, the conclusions of
systematic reviews and meta-analyses based on published
evidence alone may be misleading [5,7,38]. This is a seri-
ous concern as these documents are being used increas-
ingly to support decision making in the health care
system. Reporting bias may consequently result in inap-
propriate health care decisions by policy makers and cli-
nicians, which harm patients, waste resources, and
misguide future research [4,5,34].
Trial registration and public access to study data
There is an ethical obligation to publish research findings
[120,147-150]. For example, patients who participate in
clinical trials do so in the belief that they are contributing
to medical progress, and this will only be the case if these
trials are published. Deliberate non- or selective report-
ing represents unethical behaviour and scientific miscon-
duct [34,147]. Public access to study data may also help
identify safety problems at an earlier stage, which in the
past have in some cases not always been detected by reg-
ulatory authorities [151-153]. Two concepts can help
solve the issue of reporting bias: firstly, the mandatory
and prospective registration of clinical trials, and sec-
ondly, the mandatory publication of full study results in
results databases after study completion.
Non-industry initiatives
One of the first searchable computerized international
registries of clinical trials was introduced in the United
States in 1967; since then, several national and interna-
tional trial registries have been created [154], such as the
US government's trial registry and results database Clini-
calTrials.gov (see Tse et al for an update on this registry
[155,156]). The various controversies surrounding
reporting bias, particularly the non-reporting of safety
data, accelerated the movement both for trial registration
and the establishment of results databases. Numerous
researchers, organizations, regulatory and governmental
authorities started various initiatives to achieve these
goals [148,157-165].
In 2004, the International Committee of Medical Jour-
nal Editors (ICMJE) announced that it would make regis-
tration of clinical trials in a public registry a condition of
consideration for publication [158]; this statement has
since been updated [166,167].
In 2006, the WHO established the International Clini-
cal Trials Registry Platform (ICTRP) in an initiative to
bring national trial registries together in a global network
providing a single point of access to registered trials
[157]. However, to date no consensus has been found
between the parties involved concerning which charac-
teristics must be made publicly available at registration
[168].
Section 801 of the US FDA Amendments Act 2007
(FDAAA, [169]) requires the registration at inception of
all clinical trials involving a drug, biological product, or
device regulated by the FDA. Trials must be registered on
ClinicalTrials.gov and a defined set of results must be
posted in the same registry within 12 months of study
completion. Exceptions are phase I drug trials and early
feasibility device trials. Non-compliance is sanctioned
with monetary fines [163,170].
In 2004, the European Agency for the Evaluation of
Medicinal Products (now European Medicines Agency)
launched the European clinical trials database EudraCT
(eudract.emea.europa.eu) to provide national authorities
with a common set of information on clinical trials con-
ducted in the EU. The database was initially supposed to
be available only to the responsible authorities of the
member states, as well as to the European Commission
and the European Medicines Agency [171]. In 2006, the
regulation on medicinal products for paediatric use was
published, which required that information about Euro-McGauran et al. Trials 2010, 11:37
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pean paediatric clinical trials of investigational medicinal
products was to be made publicly available on EudraCT
[172,173], and in February 2009, the European Commis-
sion published a guideline including the list of data fields
to be made public [174]. On the same date, a similar list
was published for all trials [175]. However, the legal obli-
gation to publish information on trials in adults is not
fully clear, and it is also unclear when all relevant infor-
mation from EudraCT will be made publicly accessible.
With the introduction of the above-mentioned legisla-
tion, regulatory agencies are on the one hand helping to
solve the problem of reporting bias, but on the other
hand, they are also part of the problem: several of the
examples identified refer to the non-publication or active
w i t h h o l d i n g  o f  s t u d y  d a t a  b y  r e g u l a t o r y  a g e n c i e s
[83,94,109,133]. This is partly due to existing confidenti-
ality regulations such as Exemption 4 of the US Freedom
of Information Act [176]. To solve the problems resulting
from this situation, current legislation has to be changed
to allow for the publication of comprehensive informa-
tion on study methods and results by regulatory agencies.
In his essay "A taxpayer-funded clinical trials registry and
results database", Turner called for increased access to
the FDA information sources, which would at least enable
the assessment of drugs marketed in the USA [92].
Although the FDA posts selected reviews of NDAs on its
website after the approval process following the Elec-
tronic Freedom of Information Act [177], the availability
of these reviews is limited [92]. Moreover, according to
the FDAAA, the results of older trials of approved drugs
or of drugs that were never approved need not be dis-
closed [170], which is why a retrospective registry and
results database is needed [178].
Industry initiatives
In 2002, the US Pharmaceutical Research and Manufac-
turers Association (PhRMA) member companies com-
mitted themselves to the registration of all hypothesis-
testing clinical trials at initiation and to the timely disclo-
sure of summary results, regardless of outcome [179,180].
PhRMA also launched the clinical study results database
ClinicalStudyResults.org in 2004. In 2005, a similar com-
mitment was made by several pharmaceutical industry
associations [181], which has since been updated [182].
Following the legal settlement in the paroxetine case,
GSK established a trial registry on its website 
gsk-clinicalstudyregister.com
 and other large companies have followed. In 2008, the
German Association of Research-Based Pharmaceutical
Companies (VFA) published a position paper on the issue
of publication bias and claimed that, because of the vol-
untary self-commitment of the pharmaceutical industry
and the introduction of legislation for the reporting of
study data, publication bias had become a "historical"
topic [183]. However, even after the update of the posi-
tion paper in January 2009 [184], in Germany alone fur-
ther attempts by drug companies to withhold study data
have occurred [69], which shows that voluntary self-com-
mitment is insufficient.
Conclusions
Reporting bias is widespread in the medical literature and
has harmed patients in the past. Mandatory prospective
registration of trials and public access to study data via
results databases need to be introduced on a worldwide
level. This would help fulfil ethical obligations towards
patients by enabling proactive publication and indepen-
dent reviews of clinical trial data, and ensure a basis for
fully informed decision making in the health care system.
Otherwise, clinical decision making based on the "best
evidence" will remain an illusion.
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